Investigational Drug Information for Vaborbactam
✉ Email this page to a colleague
What is the drug development status for Vaborbactam?
Vaborbactam is an investigational drug.
There have been 5 clinical trials for Vaborbactam.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 20th 2014.
The most common disease conditions in clinical trials are Infections, Infection, and Pneumonia. The leading clinical trial sponsors are Department of Health and Human Services, Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), and Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.).
There are fifteen US patents protecting this investigational drug and one hundred and thirty-eight international patents.
Summary for Vaborbactam
| US Patents | 15 |
| International Patents | 138 |
| US Patent Applications | 62 |
| WIPO Patent Applications | 54 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2014-11-20) |
| Vendors | 33 |
Recent Clinical Trials for Vaborbactam
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia | Melinta Therapeutics, Inc. | Phase 3 |
| Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers | Biomedical Advanced Research and Development Authority | Phase 1 |
| Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers | Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Phase 1 |
Clinical Trial Summary for Vaborbactam
Top disease conditions for Vaborbactam
Top clinical trial sponsors for Vaborbactam
US Patents for Vaborbactam
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Vaborbactam | ⤷ Try a Trial | Cyclic boronic acid ester derivatives and methods of making the same | Rempex Pharmaceuticals, Inc. (San Diego, CA) | ⤷ Try a Trial |
| Vaborbactam | ⤷ Try a Trial | Beta-lactamase inhibitors | Novartis AG (Basel, CH) | ⤷ Try a Trial |
| Vaborbactam | ⤷ Try a Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Try a Trial |
| Vaborbactam | ⤷ Try a Trial | Pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (San Diego, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Vaborbactam
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Vaborbactam | Australia | AU2011289615 | 2030-08-10 | ⤷ Try a Trial |
| Vaborbactam | Brazil | BR112013003045 | 2030-08-10 | ⤷ Try a Trial |
| Vaborbactam | Canada | CA2807546 | 2030-08-10 | ⤷ Try a Trial |
| Vaborbactam | Chile | CL2013000399 | 2030-08-10 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
